Search
First Tracks Biotherapeutics Ord Shs
TRAXAdd to Watchlist
47.100USD
-1.600-3.29%
Close 11-13 16:00（ET）
1.98BMarket Cap
0.00P/E TTM
TRAX Analyst Recommendation Trends
In the current month, TRAX has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRAX average Analyst price target in the last month is 73.182.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
2
2
2
2
0
0
8
8
6
6
5
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
8
8
7
6
0
0
Financial Forecasting
Based on analysts' estimates, TRAX EPS is projected to reach -0.738 in FY2026Q4, following reported EPS of -0.877 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.52
-0.83
-0.90
-0.74
-0.78
Actual
-1.45
-0.95
-0.88
--
--
Surprise
-178.32%
-14.62%
+2.88%
--
--
FAQs
What is First Tracks Biotherapeutics Ord Shs's expected revenue for the next quarter?
First Tracks Biotherapeutics Ord Shs's expected revenue is 4.45M.
How have First Tracks Biotherapeutics Ord ShsTRAX's recent earnings per share performed?
The market expectation was USD -0.88, while First Tracks Biotherapeutics Ord ShsTRAX's earnings per share (EPS) for the previous quarter was USD -0.95. EPS for the next quarter is expected at USD -0.74.
What is the analyst rating for First Tracks Biotherapeutics Ord Shs?
Based on the ratings of First Tracks Biotherapeutics Ord Shs's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.